Center for Cancer Research, National Cancer Institute
Mark Roschewski M.D is a clinician scientist and the Clinical Director of the Lymphoid Malignancies Branch of the Center for Cancer Research, National Cancer Institute in Bethesda, MD. He began his career at Walter Reed Army Medical Center and after completing 12 years of active-duty Army service time, he transferred to the U.S. Public Health Service and joined the faculty at the NCI in 2013.
Dr. Roschewski earned his B.A. degrees at University of Notre Dame and received his M.D. from the University of Nebraska Medical Center in Omaha, NE. He completed both internship and residency in internal medicine at Eisenhower Army Medical Center in Augusta, GA and hematology-oncology fellowship in medical oncology at the Walter Reed Army Medical Center in Washington, DC.
The primary goal of his research team is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, EBV-associated lymphomas, and CNS lymphomas. Recent studies have demonstrated highly effective therapy for subtypes of DLBCL such as primary mediastinal B-cell lymphoma and Burkitt lymphoma. In addition, their group has demonstrated the effectiveness of targeted therapies including inhibitors of Bruton tyrosine kinase. As a single agent, ibrutinib is effective in both primary and secondary CNS lymphomas; findings that have led to changes in treatment paradigms. In addition, his clinical team collaborates to develop circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in DLBCL and other lymphoma subtypes.